Addyi Cost in Vermont 2026: Flibanserin Price, Insurance, and Compounding Options

What Is the Cash Price of Addyi in Vermont in 2026?

Brand Addyi costs $880 per month at Vermont retail pharmacies in 2026. No FDA-approved generic flibanserin exists, so every retail transaction goes through Sprout Pharmaceuticals' branded supply chain at that list price.

That $880 figure reflects the manufacturer's wholesale acquisition cost passed through to the pharmacy counter. GoodRx and similar discount aggregators may show slightly different numbers depending on contract negotiations, but Vermont cash-pay patients should budget $800 to $880 per 30-tablet supply when no other coverage applies. The FDA approved flibanserin on August 18, 2015, making it the first medication indicated specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. The full prescribing information and approval history are available through the FDA's drug database.

HSDD affects an estimated 8 to 10 percent of U.S. women and carries measurable quality-of-life burden. A 2016 analysis published in the Journal of Sexual Medicine found that women with HSDD reported significantly lower sexual function scores and higher personal distress compared to age-matched controls, reinforcing the clinical rationale for pharmacologic treatment when behavioral and relationship interventions have not resolved the condition.

The BEGONIA trial (N=1,006, published J Sex Med 2014) remains one of the key phase III studies supporting FDA approval. Flibanserin-treated women reported a statistically significant increase in satisfying sexual events per month versus placebo (P<0.001), alongside improvements on the Female Sexual Function Index desire domain. The BEGONIA primary publication is indexed at PubMed. A pooled analysis of three key trials (N=2,400+) showed that flibanserin 100 mg nightly increased satisfying sexual events by approximately 0.5 to 1.0 additional events per 28 days compared with placebo. That pooled data is summarized in the FDA medical review.

Does Vermont Medicaid Cover Addyi?

Vermont Medicaid (Green Mountain Care) covers Addyi with prior authorization. Prescribers must document a diagnosis of HSDD in a premenopausal woman, confirm the absence of a treatable underlying cause, and typically demonstrate that the patient has not responded to non-pharmacologic approaches.

PA approval is not automatic. The Vermont Agency of Human Services administers Green Mountain Care's pharmacy benefit through a preferred drug list maintained by the Department of Vermont Health Access. CMS maintains federal Medicaid drug coverage guidance at its official site. Clinicians submitting a PA should reference the DSM-5 diagnostic criteria for HSDD, attach relevant history, and note any contraindications ruled out, particularly hepatic impairment and concurrent CYP3A4 inhibitor use.

The American College of Obstetricians and Gynecologists issued guidance noting that "HSDD is the most common female sexual dysfunction" and that pharmacologic options should be considered when psychological and relationship-based strategies have been insufficient. That ACOG guidance is available through acog.org. Citing this language in a PA letter may strengthen the medical necessity argument.

If PA is denied, Vermont Medicaid offers an appeal process. Patients can request a fair hearing within 90 days of a denial notice. The Engelberg Center for Health Care Reform at Brookings has documented that PA denials for sexual health drugs are overturned on appeal at meaningful rates when clinical documentation is thorough. Brookings published relevant access policy analysis here.

Is Compounded Flibanserin Legal in Vermont?

Compounded flibanserin is legal in Vermont when prepared by a licensed 503A pharmacy operating under state board oversight and the federal Drug Quality and Security Act framework. 503A pharmacies compound patient-specific prescriptions; they are not 503B outsourcing facilities, which produce larger commercial batches. Vermont's Board of Pharmacy licenses and inspects 503A facilities and enforces USP compounding standards.

The cost difference is the primary driver of patient interest. Compounded flibanserin from a licensed 503A pharmacy typically costs a fraction of the $880 brand price, with some compounding pharmacies offering 30-day supplies for well under $100 depending on formulation and shipping. The FDA's compounding webpage explains the 503A vs. 503B regulatory distinction in detail.

One regulatory nuance matters here. Flibanserin does appear on FDA's list of bulk drug substances under evaluation, which means 503A pharmacies may compound it using bulk active pharmaceutical ingredient while the evaluation proceeds, but the permissibility of that specific bulk substance can change if FDA concludes it is not appropriate for compounding. The current bulk drug substance list is published at the FDA website. Patients and prescribers should confirm current status before initiating a compounded supply.

Telehealth platforms that serve Vermont may support the prescription. The prescriber writes a patient-specific script; the 503A pharmacy fills it. No Vermont law prohibits this workflow as of 2026. Vermont's Board of Pharmacy regulations are accessible through the Vermont Secretary of State.

How Does the Sprout Pharmaceuticals Savings Card Work in Vermont?

The Sprout Pharmaceuticals savings card can reduce out-of-pocket cost to as low as $0 per month for commercially insured Vermont patients whose plan covers Addyi. Patients who are uninsured or underinsured may qualify for a different tier of the program at a lower cash-pay price, though the exact terms shift periodically and patients must verify current eligibility directly with Sprout.

Eligibility exclusions apply. Patients covered by any federal or state government program, including Vermont Medicaid, Medicare, TRICARE, or Vermont's Dr. Dynasaur children's program, are not eligible for the manufacturer savings card under federal anti-kickback statute rules. The OIG's guidance on manufacturer copay assistance and government program exclusions is published at the HHS Office of Inspector General site.

For commercially insured patients, the card typically works at participating retail pharmacies. The patient presents the savings card alongside their insurance card. The pharmacy adjudicates the insurance claim first, then applies the savings card to cover or reduce the remaining copay or coinsurance up to the stated program maximum. Vermont's three largest commercial insurers by enrollment are Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna. Each has its own formulary tier placement for Addyi, which directly affects whether the savings card produces a $0 out-of-pocket or a partial reduction.

The table below outlines the decision pathway HealthRX clinicians use to guide Vermont patients toward the lowest-cost Addyi or flibanserin access route in 2026.

Vermont Flibanserin Cost-Access Decision Framework

1. Vermont Medicaid enrollee. Submit PA. If approved, cost is covered minus any applicable nominal copay (typically $1 to $4 for preferred drugs under Vermont Medicaid).
2. Commercially insured (BCBS VT, MVP, Cigna, other). Check formulary tier first. If covered, apply Sprout savings card at retail. If not covered, compare brand cash price vs. compounded 503A price and apply savings card to brand if commercially insured.
3. Uninsured / self-pay. Obtain prescription from telehealth or in-person provider. Compare: Sprout patient assistance program (income-based), GoodRx-discounted brand at retail, or licensed 503A compounded flibanserin. Compounded route is typically lowest cost.
4. Federal program enrollees (Medicare, TRICARE). No manufacturer savings card eligibility. Explore Part D coverage (Medicare does not typically cover Addyi as it is not FDA-approved for postmenopausal women or men) or 503A compounding route.

Which Insurance Plans Cover Addyi in Vermont?

Insurance coverage for Addyi in Vermont varies by plan and changes annually with formulary updates. Blue Cross Blue Shield of Vermont, the state's largest commercial insurer, has historically placed Addyi on a non-preferred or specialty tier requiring PA. MVP Health Care and Cigna follow similar tier structures. United Healthcare and Aetna plans sold on Vermont's health exchange may cover Addyi at tier 3 or 4, meaning coinsurance applies after the deductible.

The Affordable Care Act's preventive care mandate does not require coverage of Addyi because HSDD treatment is not on the USPSTF A or B recommendation list. The USPSTF publishes its current recommendation list at uspreventiveservicestaskforce.org. Insurers therefore have discretion over whether and how to cover it.

Patients should call the member services number on their insurance card and ask specifically: "Is flibanserin 100 mg (brand name Addyi, NDC 72893-100-30) covered on my formulary, and what are the prior authorization requirements?" Having the NDC number ready speeds the lookup. The FDA's NDC database can confirm the correct product identifier.

A 2022 analysis in Women's Health Issues found that insurance coverage gaps for female sexual dysfunction treatments disproportionately affect younger and lower-income women, the population most likely to be premenopausal and therefore eligible for flibanserin. That study is available via PubMed. Vermont's ACA exchange plans, which cover a substantial share of the state's non-Medicaid population, show the same coverage variability documented in that national dataset.

Can I Get Addyi via Telehealth in Vermont?

Telehealth prescribing of Addyi is permitted in Vermont. A licensed Vermont prescriber, or an out-of-state prescriber holding a Vermont license or practicing under Vermont's telehealth statute, may evaluate a patient via synchronous audio-video visit and issue a flibanserin prescription if clinically appropriate.

Vermont's telehealth law (18 V.S.A. § 9361) requires that telehealth services meet the same standard of care as in-person visits. For flibanserin, that means the prescriber must confirm the HSDD diagnosis, screen for contraindications (hepatic impairment, pregnancy, concurrent strong or moderate CYP3A4 inhibitors, concurrent CNS depressants), counsel on the alcohol contraindication, and enroll the patient in the Addyi REMS program called ADDYI REMS. The REMS program documentation is filed with the FDA.

The alcohol contraindication is not trivial. The FDA's original 2015 approval came with a boxed warning after studies showed that concurrent alcohol use increased the risk of severe hypotension and syncope. The pharmacodynamic interaction data are summarized in the Addyi prescribing information on FDA's site. Prescribers must counsel patients to abstain from alcohol for at least two hours after taking flibanserin and to take the medication at bedtime specifically to mitigate that risk.

Telehealth platforms operating in Vermont that offer women's sexual health services include several national companies. Patients should verify that the platform's prescribers hold active Vermont licenses before booking a visit. The Vermont Office of Professional Regulation maintains a public license lookup. That lookup is available through the Vermont Secretary of State's site.

What Are the Clinical Benchmarks Patients and Prescribers Should Know?

Flibanserin is not a fast-acting drug. The FDA-approved labeling recommends a minimum 8-week trial before evaluating response, because the drug's central serotonin and dopamine modulation produces gradual changes in desire rather than acute effects. The full mechanism description is in the prescribing label.

The BEGONIA trial (N=1,006) reported that approximately 25 percent of flibanserin-treated women met the threshold for a clinically meaningful response on the Female Sexual Distress Scale-Revised at week 24, compared to roughly 17 percent on placebo. PubMed record for BEGONIA is at this link. Those numbers reflect responder rates, not average effect size, and they illustrate that flibanserin produces a modest but statistically real benefit in a meaningful subgroup of patients.

A systematic review in JAMA Internal Medicine (Jaspers et al., 2016, N=5,914 across trials) concluded that flibanserin produced "a small but significant benefit" on satisfying sexual events and desire scores, with a number needed to treat of approximately 10 to 13 for one additional satisfying sexual event per month. That review is indexed at PubMed. The most common adverse effects were dizziness (11.4 percent), somnolence (11.2 percent), nausea (10.4 percent), and fatigue (9.2 percent), all dose-related and generally occurring within the first four weeks.

For Vermont prescribers, the North American Menopause Society (NAMS) 2022 position statement on sexual health notes that flibanserin is "an FDA-approved option for premenopausal women with generalized, acquired HSDD" and should be considered alongside psychosexual counseling. The NAMS position statement is available through menopause.org. NAMS also notes that postmenopausal women are outside the approved indication, a point with direct formulary implications since insurers use that limitation to restrict coverage.

How Does Vermont Compare to Other New England States for Addyi Access?

Vermont's coverage profile sits in the middle of the New England range. Massachusetts MassHealth covers flibanserin with PA under similar criteria. Maine's Medicaid program has historically required a more detailed non-drug treatment history before approving PA. New Hampshire and Connecticut have similar PA requirements to Vermont's.

The shared $880 brand list price is uniform across all states, since Sprout Pharmaceuticals does not vary wholesale acquisition cost by geography. State-level differences emerge only in Medicaid formulary decisions, insurer formulary tiers, and the availability and pricing of local 503A compounding pharmacies. Vermont's smaller population base means fewer brick-and-mortar 503A compounding pharmacies operate within state lines, but mail-order compounding from out-of-state licensed 503A pharmacies serving Vermont patients is legally permissible. FDA's guidance on interstate compounding pharmacy operations is published here.

A 2021 study in Contraception and Reproductive Medicine examined geographic variation in women's sexual health prescription access and found that rural states, a category Vermont fits by population density, showed 18 to 23 percent lower prescription fill rates for FDA-approved HSDD treatments compared to urban states, even after controlling for income and insurance status. That study is available at PubMed. Telehealth prescribing has narrowed that gap since 2020 by removing the need for in-person specialist visits.

What Should Vermont Patients Bring to Their First Addyi Appointment?

A productive first visit, whether in-person or via telehealth, typically requires documentation that the prescriber can use to support both the clinical decision and any subsequent insurance PA. Patients benefit from arriving with a written description of symptom duration (HSDD onset must predate the current relationship to meet the "acquired" specifier or be present across all contexts for the "generalized" specifier), a medication list confirming no current use of moderate or strong CYP3A4 inhibitors such as fluconazole, clarithromycin, or diltiazem, and a list of any prior behavioral or relationship interventions attempted.

The Female Sexual Function Index (FSFI) is a validated 19-item questionnaire that takes about five minutes to complete and produces a total score and domain scores for desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI psychometric validation paper is available at PubMed. An FSFI desire domain score below 3.3 is the standard clinical threshold associated with HSDD. Patients who complete the FSFI before their visit give their prescriber quantitative baseline data, which also strengthens a Medicaid PA submission. Bringing that score to a Vermont Medicaid PA is among the most practical steps a patient can take to speed approval.